About aim immunotech - AIM
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.
AIM At a Glance
AIM ImmunoTech, Inc.
2117 SW Highway 484
Ocala, Florida 34473
| Phone | 1-352-448-7797 | Revenue | 88.00K | |
| Industry | Pharmaceuticals: Major | Net Income | -13,958,000.00 | |
| Sector | Health Technology | Employees | 19 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
AIM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 20.785 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.357 |
| Enterprise Value to Sales | 41.796 |
| Total Debt to Enterprise Value | 1.331 |
AIM Efficiency
| Revenue/Employee | 4,631.579 |
| Income Per Employee | -734,631.579 |
| Receivables Turnover | 12.571 |
| Total Asset Turnover | 0.003 |
AIM Liquidity
| Current Ratio | 0.529 |
| Quick Ratio | 0.529 |
| Cash Ratio | 0.49 |
AIM Profitability
| Gross Margin | -284.091 |
| Operating Margin | -11,961.364 |
| Pretax Margin | -15,861.364 |
| Net Margin | -15,861.364 |
| Return on Assets | -48.745 |
| Return on Equity | N/A |
| Return on Total Capital | 285.615 |
| Return on Invested Capital | N/A |
AIM Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -100.184 |
| Total Debt to Total Assets | 84.677 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -22.447 |